Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LIPO | US
0
0%
Healthcare
Biotechnology
30/06/2024
24/04/2026
0.03
0.03
0.03
0.03
Lipella Pharmaceuticals Inc. a clinical-stage biotechnology company focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10 a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310 a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh Pennsylvania.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
561.2%1 month
448.3%3 months
359.2%6 months
248.2%-
-
2.35
0.05
0.04
-4.40
6.48
-
-4.74M
244.76K
244.76K
-
-697.93
-
27.90
-171.56
0.21
3.38
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.05
Range1M
0.13
Range3M
0.30
Rel. volume
0.28
Price X volume
209.10
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Hepion Pharmaceuticals Inc | HEPA | Biotechnology | 0.04 | 231.97K | 4.71% | n/a | 4.33% |
| Innovation Pharmaceuticals Inc | IPIX | Biotechnology | 0.0003 | 155.50K | -70.00% | n/a | 20.48% |
| Windtree Therapeutics Inc | WINT | Biotechnology | 0.0224 | 82.42K | 1.82% | n/a | 36.99% |
| Syros Pharmaceuticals Inc | SYRS | Biotechnology | 0.0002 | 5.36K | -33.33% | n/a | -954.99% |
| Calithera Biosciences Inc | CALA | Biotechnology | 0.0003 | 1.46K | 200.00% | n/a | 8.17% |
| XOMAP | XOMAP | Biotechnology | 26.125 | 0 | 26.27 | 121.93% | |
| XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock | XOMAO | Biotechnology | 25.4278 | 0 | -0.44% | 25.57 | 121.93% |
| Vaxxinity Inc. Class A Common Stock | VAXX | Biotechnology | 0 | 0 | -100.00% | n/a | 113.12% |
| SABSW | SABSW | Biotechnology | 0.0185 | 0 | 0.17 | 11.58% | |
| Revolution Medicines Inc. Warrant | RVMDW | Biotechnology | 4.43 | 0 | 3.02% | n/a | 5.40% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
No data | |||||||
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.40 | 0.53 | Cheaper |
| Ent. to Revenue | 6.48 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.35 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 359.15 | 72.80 | Riskier |
| Debt to Equity | 0.05 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 244.76K | 3.66B | Emerging |